{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:45Z","timestamp":1787026665027,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gallbladder cancer is an extremely aggressive malignant tumor of the digestive system. It presents with no obvious symptoms in its early stages, meaning most patients are already in advanced stages at diagnosis. The response to neoadjuvant therapy for gallbladder cancer is poor, and the majority of patients with advanced gallbladder cancer cannot achieve tumor downstaging through drug treatment to become eligible for surgery. This case focuses on discussing the selection of immunotherapy drugs and the determination of their treatment cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>This case report describes a patient with gallbladder cancer and intrahepatic metastases. Following contrast-enhanced computed tomography (CECT) evaluation, R0 resection of the lesions was deemed unfeasible. The patient underwent conversion therapy with camrelizumab combined with gemcitabine and cisplatin. The patient responded well to this regimen, with rapid tumor shrinkage after three cycles of treatment. Grade IV neutropenia developed during therapy but resolved without serious consequences following prompt intervention. After reassessment, the patient underwent open cholecystectomy combined with segmental resection of the liver segments IVb\/V, lymph node dissection, and high hepaticojejunal anastomosis. Postoperative recovery was favorable, with PFS reaching 18 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The regimen of camrelizumab combined with gemcitabine and cisplatin demonstrated potential conversion therapy value in this patient with advanced gallbladder cancer. However, its definitive efficacy and the specific role of camrelizumab still require validation through large-scale clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1724263","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:44:45Z","timestamp":1779191085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Successful conversion of gallbladder cancer with intrahepatic metastases using camrelizumab combined with gemcitabine and cisplatin"],"prefix":"10.3389","volume":"17","author":[{"given":"Dongdong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyuan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyue","family":"Du","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyang","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Gansu Provincial Second People\u2019s Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanteng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Lanzhou University Second Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12957-020-01934-4","article-title":"Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature","volume":"18","author":"Soni","year":"2020","journal-title":"World J Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10343-6","article-title":"Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis","volume":"16","author":"Choi","year":"2022","journal-title":"Hepatol Int"},{"key":"B3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s12885-020-07139-y","article-title":"Effect of diabetes mellitus on survival in patients with gallbladder cancer: a systematic review and meta-analysis","volume":"20","author":"Jing","year":"2020","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2020.12.006","article-title":"Gallbladder cancer who is really cured","volume":"23","author":"de Aretxabala","year":"2021","journal-title":"HPB: Off J Int Hepato Pancreato Biliary Assoc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2021.04.051","article-title":"Degradable magnesium implants inhibit gallbladder cancer","volume":"128","author":"Peng","year":"2021","journal-title":"Acta Biomater"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.03.003","article-title":"Epigenetic biomarkers in gallbladder cancer","volume":"6","author":"Tiwari","year":"2020","journal-title":"Trends Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11985-4","article-title":"Can we predict surgical futility\/cure in gallbladder cancer","volume":"29","author":"Grotz","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09629-0","article-title":"Conditional recurrence-free survival for patients with gallbladder cancer: a personalized resource for patients and providers","volume":"28","author":"Ejaz","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217067","article-title":"GPRC5A promotes gallbladder cancer metastasis by upregulating TNS4 via the JAK2-STAT3 pathway","volume":"598","author":"Yang","year":"2024","journal-title":"Cancer Lett"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3892\/ijo.2023.5604","article-title":"Long non-coding RNAs in gallbladder cancer: from mechanisms to therapeutic opportunities (review)","volume":"64","author":"He","year":"2024","journal-title":"Int J Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i22.3978","article-title":"Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update","volume":"23","author":"Sharma","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071748","article-title":"Evolving role of immunotherapy in advanced biliary tract cancers","volume":"14","author":"Kang","year":"2022","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2022121","article-title":"Camrelizumab: an investigational agent for hepatocellular carcinoma","volume":"31","author":"Xu","year":"2022","journal-title":"Expert Opin Invest Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae154","article-title":"Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study","volume":"29","author":"Jing","year":"2024","journal-title":"Oncologist"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16376","article-title":"Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers","volume":"116","author":"Tian","year":"2025","journal-title":"Cancer Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4251\/wjgo.v16.i1.13","article-title":"New trends in diagnosis and management of gallbladder carcinoma","volume":"16","author":"Et","year":"2024","journal-title":"World J Gastrointestinal Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1724263\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:44:51Z","timestamp":1779191091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1724263\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1724263"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1724263","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1724263"}}